22 results
424B5
INM
InMed Pharmaceuticals Inc
3 Jun 22
Prospectus supplement for primary offering
9:45pm
, attain profitability or commercialize our products.
Increased scrutiny on drug pricing or changes in pricing regulations could restrict the amount … that we are able to charge for our Product Candidates, which could adversely affect our revenue and results of operations.
Drug pricing
424B3
INM
InMed Pharmaceuticals Inc
25 Apr 22
Prospectus supplement
5:02pm
reforms may compromise our ability to generate revenue, attain profitability or commercialize our products.
Increased scrutiny on drug pricing … and results of operations.
Drug pricing by pharmaceutical companies is currently under increased scrutiny and is expected to continue to be the subject
424B3
INM
InMed Pharmaceuticals Inc
7 Apr 22
Prospectus supplement
4:46pm
to generate revenue, attain profitability or commercialize our products.
Increased scrutiny on drug pricing or changes in pricing regulations could … with respect to pharmaceutical drug pricing practices, including in connection with the investigation of specific price increases by several pharmaceutical
S-3
765qzun6tad
4 Feb 22
Shelf registration
4:36pm
10-K
4ezaxul4bwxlr1
24 Sep 21
Annual report
7:31am
424B3
vtk s4q42e4y5q
22 Jul 21
Prospectus supplement
10:27am
424B3
6exsmfgx
16 Mar 21
Prospectus supplement
12:00am
10-Q
jthqniyhqz it
17 Dec 20
Quarterly report
12:00am
424B4
5g06o
13 Nov 20
Prospectus supplement with pricing info
8:52pm
S-1
xrik5kdl6uuaux
19 Jun 20
IPO registration
4:59pm